Immunocore Holdings (IMCR) Common Equity (2019 - 2026)

Immunocore Holdings (IMCR) has reported Common Equity for 8 consecutive years, with $393.7 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity rose 4.01% year-over-year to $393.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $393.7 million (up 4.01% YoY) and the FY2025 annual result came in at $381.0 million, up 5.63% from the prior year.
• Common Equity advanced to $393.7 million in Q1 2026 per IMCR's latest filing, from $381.0 million in the prior quarter.
• Over the last five years, Common Equity for IMCR reached as high as $396.6 million in Q3 2025 and fell as low as $207.3 million in Q2 2022.
• A 5-year average of $355.9 million and a median of $360.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity surged 69.49% — and 2024, when it slipped 2.2%.
• Year by year, Common Equity stood at $327.0 million in 2022, then climbed by 12.81% to $368.8 million in 2023, then decreased by 2.2% to $360.7 million in 2024, then rose by 5.63% to $381.0 million in 2025, then grew by 3.32% to $393.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $393.7 million, $381.0 million, and $396.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.